HighTower Advisors LLC Has $41.97 Million Holdings in Novartis AG $NVS

HighTower Advisors LLC grew its position in shares of Novartis AG (NYSE:NVS) by 1.2% in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 267,821 shares of the company’s stock after buying an additional 3,182 shares during the quarter. HighTower Advisors LLC’s holdings in Novartis were worth $41,973,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors have also made changes to their positions in NVS. Tanager Wealth Management LLP acquired a new stake in Novartis in the second quarter valued at approximately $201,000. Ameritas Advisory Services LLC raised its holdings in shares of Novartis by 94.4% during the 2nd quarter. Ameritas Advisory Services LLC now owns 4,647 shares of the company’s stock valued at $728,000 after purchasing an additional 2,256 shares in the last quarter. Kintra Wealth LLC raised its holdings in shares of Novartis by 48.7% during the 2nd quarter. Kintra Wealth LLC now owns 5,118 shares of the company’s stock valued at $776,000 after purchasing an additional 1,677 shares in the last quarter. HB Wealth Management LLC lifted its stake in shares of Novartis by 6.8% in the 2nd quarter. HB Wealth Management LLC now owns 19,549 shares of the company’s stock valued at $3,064,000 after purchasing an additional 1,237 shares during the last quarter. Finally, Angeles Wealth Management LLC boosted its holdings in Novartis by 3.8% in the second quarter. Angeles Wealth Management LLC now owns 4,448 shares of the company’s stock worth $697,000 after purchasing an additional 162 shares in the last quarter. Institutional investors own 13.12% of the company’s stock.

Novartis Price Performance

Shares of Novartis stock opened at $159.95 on Tuesday. The company has a current ratio of 0.86, a quick ratio of 0.67 and a debt-to-equity ratio of 0.89. The firm has a fifty day simple moving average of $155.79 and a 200-day simple moving average of $153.67. The stock has a market capitalization of $305.21 billion, a price-to-earnings ratio of 24.13, a PEG ratio of 3.12 and a beta of 0.45. Novartis AG has a 1-year low of $121.57 and a 1-year high of $170.46.

Novartis (NYSE:NVS) last posted its earnings results on Tuesday, June 30th. The company reported $2.41 earnings per share (EPS) for the quarter. The business had revenue of $14.95 billion for the quarter. Novartis had a net margin of 23.29% and a return on equity of 38.56%. On average, sell-side analysts expect that Novartis AG will post 8.84 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several equities analysts have weighed in on the company. Weiss Ratings restated a “buy (b)” rating on shares of Novartis in a report on Friday, July 24th. Citigroup reiterated a “buy” rating on shares of Novartis in a research note on Wednesday, July 22nd. Seven analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat.com, Novartis presently has a consensus rating of “Hold” and an average price target of $141.20.

Key Stories Impacting Novartis

Here are the key news stories impacting Novartis this week:

• Positive Sentiment: Novartis reaffirmed its sales guidance through 2030 despite the del-desiran setback, providing some support for the company’s near- and medium-term outlook. Novartis announces trial setback on del-desiran drug
• Positive Sentiment: Remibrutinib could represent a significant opportunity in multiple sclerosis, with Bank of America estimating potential peak annual sales of roughly $3 billion if the drug wins regulatory approval and captures meaningful market share. However, regulatory and competitive risks remain. Novartis has a potential $3 billion MS opportunity
• Neutral Sentiment: Del-desiran was one of three neuromuscular therapies Novartis obtained through its approximately $12 billion acquisition of Avidity Biosciences, increasing investor focus on the deal’s ability to produce valuable pipeline assets. Novartis says neuromuscular drug candidate misses goal
• Negative Sentiment: A late-stage del-desiran trial for myotonic dystrophy failed to meet its key efficacy measure. The result marked another pipeline disappointment within a week and raised concerns about the prospects of the Avidity acquisition. Pharma major plummets after third trial disappointment in a week
• Negative Sentiment: Pelacarsen failed to reduce cardiovascular events such as death, heart attack or stroke, despite lowering harmful Lp(a) cholesterol. The failure undermines the drug’s multibillion-dollar commercial potential and increases pressure on Novartis to deliver success from other pipeline programs. Cholesterol drug setback casts doubt over multibillion-dollar race

Novartis Company Profile

Novartis is a Swiss multinational pharmaceutical company headquartered in Basel that researches, develops, manufactures and commercializes prescription medicines and related health-care products. Formed through the 1996 merger of Ciba-Geigy and Sandoz, Novartis operates globally and focuses on bringing therapeutics from discovery through clinical development to commercial markets worldwide.

The company’s activities center on innovative pharmaceuticals across several therapeutic areas, including oncology, immunology, cardiovascular and metabolic diseases, neuroscience and ophthalmology, alongside capabilities in advanced therapies such as biologics, cell and gene therapies.